Dupilumab phase 2b study

High-dose ICS at baseline (ITT population)

![Graph showing change in ACQ-5 scores](image)

**Change from baseline in ACQ-5 scores, LS mean (± SE)**

| Week | Placebo q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q2w |
|------|-------------|----------------------|----------------------|
| 0    |             |                      |                      |
| 2    |             |                      |                      |
| 4    |             |                      |                      |
| 6    |             |                      |                      |
| 8    |             |                      |                      |
| 10   |             |                      |                      |
| 12   |             |                      |                      |
| 14   |             |                      |                      |
| 16   |             |                      |                      |
| 18   |             |                      |                      |
| 20   |             |                      |                      |
| 22   |             |                      |                      |
| 24   |             |                      |                      |

**Number of patients**

| Placebo q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q2w |
|-------------|----------------------|----------------------|
| 53          | 66                   | 75                   |
| 60          | 66                   | 71                   |
| 64          | 67                   | 74                   |
| 66          | 65                   | 71                   |
| 60          | 66                   | 66                   |
| 59          |                      |                      |

Medium-dose ICS at baseline (ITT population)

![Graph showing change in ACQ-5 scores](image)

**Change from baseline in ACQ-5 scores, LS mean (± SE)**

| Week | Placebo q2w | Matching placebo to dupilumab 200 mg q2w | Dupilumab 300 mg q2w |
|------|-------------|------------------------------------------|----------------------|
| 0    |             |                                           |                      |
| 2    |             |                                           |                      |
| 4    |             |                                           |                      |
| 6    |             |                                           |                      |
| 8    |             |                                           |                      |
| 10   |             |                                           |                      |
| 12   |             |                                           |                      |
| 14   |             |                                           |                      |
| 16   |             |                                           |                      |
| 18   |             |                                           |                      |
| 20   |             |                                           |                      |
| 22   |             |                                           |                      |
| 24   |             |                                           |                      |

**Number of patients**

| Matching placebo to dupilumab 200 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q2w |
|------------------------------------------|----------------------|----------------------|
| 172 166 165 163 167 163 164             | 160 164 162 160 158  | 158 157 160 153 133  |
| 317 306 307 299 302 300 305             | 306 300 295 295 294  | 299 289 283 239      |
| 167 160 159 161 160 158 163             | 158 153 151 158 151  | 155 152 151 148 132  |
| 323 316 309 308 298 299 304             | 305 298 298 291 285  | 288 287 277 276 238  |
| 120 275 133 268 111 238                 | 103 231 111 238 114  | 109 236 111 239 113  |